VOR
NASDAQ HealthcareVor Biopharma Inc. - Common Stock
Biotechnology
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjรถgren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
๐ Market Data
| Price | $23.01 |
|---|---|
| Volume | 771,406 |
| Market Cap | 1.25B |
| Beta | 1.720 |
| RSI (14-Day) | 69.7 |
| 200-Day MA | $15.23 |
| 50-Day MA | $18.39 |
| 52-Week High | $50.20 |
| 52-Week Low | $6.50 |
| P/E Ratio | 0.13 |
| Forward P/E | -6.04 |
| Price / Book | -8.29 |
๐ฏ Investment Strategy Scores
VOR scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (80/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ช Falling Knife (6/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find VOR in your text
Paste any article, transcript, or post โ the tool will extract VOR and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.